Table 2. Symptoms reported at late follow-up among those with PASC.
Values reported as n (%). Participants were systematically asked about 32 individual symptoms at the late follow-up visit, which took place a median of 112 days from initial COVID-19 symptom onset.
| Symptoms reported at late follow-up | All (n=82) |
HIV+ (n=39) |
HIV− (n=43) |
|---|---|---|---|
| Constitutional | |||
| Fatigue | 26 (32) | 16 (42) | 10 (23) |
| Subjective fever | 1 (1) | 1 (3) | 0 (0) |
| Chills | 2 (2) | 2 (5) | 0 (0) |
| Objective fever | 0 (0) | 0 (0) | 0 (0) |
| Upper Respiratory | |||
| Rhinorrhea | 13 (16) | 5 (13) | 8 (19) |
| Sore throat | 2 (2) | 0 (0) | 2 (5) |
| Cardiopulmonary | |||
| Cough | 7 (9) | 3 (8) | 4 (9) |
| Shortness of breath | 20 (25) | 11 (29) | 9 (21) |
| Chest pain | 7 (9) | 3 (8) | 4 (9) |
| Palpitations | 10 (12) | 4 (11) | 6 (14) |
| Fainting | 0 (0) | 0 (0) | 0 (0) |
| Gastrointestinal | |||
| Diarrhea | 7 (9) | 5 (13) | 2 (5) |
| Nausea | 9 (11) | 5 (13) | 4 (9) |
| Loss of appetite | 4 (5) | 3 (8) | 1 (2) |
| Abdominal pain | 9 (11) | 5 (13) | 4 (9) |
| Vomiting | 1 (1) | 0 (0) | 1 (2) |
| Constipation | 0 (0) | 0 (0) | 0 (0) |
| Genitourinary | |||
| Menstrual cramps | 0 (0) | 0 (0) | 0 (0) |
| Dyspareunia | 0 (0) | 0 (0) | 0 (0) |
| Rash | 8 (10) | 7 (18) | 1 (2) |
| Musculoskeletal | |||
| Myalgia | 14 (17) | 9 (24) | 5 (12) |
| Back pain | 5 (6) | 5 (13) | 0 (0) |
| Joint pain | 11 (14) | 8 (21) | 3 (7) |
| Anosmia/Dysgeusia | 14 (17) | ||
| Neurologic | |||
| Headache | 14 (17) | 9 (24) | 5 (12) |
| Concentration problems | 24 (30) | 16 (42) | 8 (19) |
| Dizziness | 11 (14) | 5 (13) | 6 (14) |
| Balance problems | 9 (11) | 6 (16) | 3 (7) |
| Neuropathy | 9 (11) | 7 (18) | 2 (5) |
| Vision problems | 11 (14) | 8 (21) | 3 (7) |
| Parosmia | 2 (2) | 0 (0) | 2 (5) |
| Trouble Sleeping | 20 (24) | 13 (34) | 7 (16) |